Helix, ProMab sign LOI for cancer therapies

15:40 EDT 4 Apr 2018 | Elsevier Business Intelligence

Helix BioPharma Corp. and ProMab Biotechnologies Inc. have signed a letter of intent for the development of chimeric antigen ...

Original Article: Helix, ProMab sign LOI for cancer therapies

More From BioPortfolio on "Helix, ProMab sign LOI for cancer therapies"